论文部分内容阅读
选择60例初诊T2DM患者经地特胰岛素联合瑞格列奈治疗12周,比较治疗前后空腹血糖(FBG)、餐后2小时血糖(PBG)、糖化血红蛋白(HbA1c)的差异,同时观察总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL-C)、血常规、肝、肾功能的变化及体重指数(BMI),低血糖的药物副作用。结果:治疗12周后,与治疗前相比,FBG、PBG、HbA1c均降低(P<0.05),TC、TG、LDL-C,血常规、肝、肾功能、BMI与治疗前相比无显著性差异(P>0.05),有低血糖反应3例次。结论:地特胰岛素联合瑞格列奈治疗初诊T2DM患者,能使血糖下降明显,且副作用轻微、安全。
Sixty patients with newly diagnosed T2DM were treated with insulin destrain and repaglinide for 12 weeks. The differences of fasting blood glucose (FBG), 2-hour postprandial blood glucose (PBG) and HbA1c before and after treatment were compared. The levels of total cholesterol (TC), triglyceride (TG), low density lipoprotein (LDL-C), blood function, liver and kidney function, body mass index (BMI) and hypoglycemic drug side effects. Results: FBG, PBG and HbA1c were lower (P <0.05), TC, TG, LDL-C, blood routine, liver and kidney function and BMI were not significantly different from those before treatment Sex differences (P> 0.05), hypoglycemia reaction in 3 cases. CONCLUSION: Dextrins combined with repaglinide can significantly reduce blood glucose in patients with newly diagnosed T2DM, with minor side effects and safety.